Infectious mononucleosis in children: clinical and laboratory rationale and economic efficiency of application of immunocorrectors

Abstract

Objective: to select the optimal, clinically and economacally effective immunocorrector for the treatment of immune-EBV — mononucleosis in children. Materials: 400 patients with primary Epstein — Barr virus infection aged 1 to 14 years. Results. The therapy by cycloferon of primary Epstein — Barr virus infection observed a statistically significant reduction in the length of stay of patients in hospital, on average, 3 bed-days. Inclusion of cycloferon, viferon in the treatment of infectious mononucleosis, reduces the severity and duration of symptoms of intoxication, the temperature reaction, hepatotoxicity, splenomegaly, lymphoproliferative syndrome. Against the background of cycloferon lower incidence of post-infection anemia was observed. Conclusion. The inclusion of immunocorrectors into therapeutic interventions in primary Epstein — Barr virus infection has been clinically and economically proved.

Keywords

• economic efficiency
• Epstein-Barr viral infection